financetom
Business
financetom
/
Business
/
China hawk to be picked for key US Commerce Dept job, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
China hawk to be picked for key US Commerce Dept job, sources say
Feb 12, 2025 6:35 AM

Feb 12 (Reuters) - President Donald Trump plans to

nominate Landon Heid, who served on the staff of the House of

Representatives' Select Committee on China, for a key post in

the U.S.-China tech battle, according to people familiar with

the matter.

Heid, a China hawk who helped set technology policy for the

congressional committee, is being tapped to be assistant

secretary of Commerce for export administration, the people

said. As such, he would help design export controls to keep AI

chips, the equipment to make them and other technology from

China and other countries.

Heid was behind a drumbeat of actions by the committee to

combat what it sees as China's threat to U.S. national security.

Last month, the committee came out in support of a strong

global licensing regime to control the development of artificial

intelligence just before the Commerce Department published a

rule to tighten the U.S. grip on AI chip flows across the globe.

The rule, which is scheduled to take effect in May, could be

changed by the Trump administration.

Heid was behind a push last year to restrict business with

BGI, WuXi Apptec, WuXi Biologics ( WXIBF ) and other

Chinese biotech firms. Though proposed legislation gained

momentum in the last Congress, it did not pass.

The White House did not immediately respond to a request for

comment. Nor did Heid.

If confirmed, Heid is expected to report to Jeffrey Kessler,

a Washington trade lawyer nominated as under secretary for the

Commerce Department's Bureau of Industry and Security (BIS).

Reuters first reported that Kessler was under consideration.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NanoVibronix Names Doron Besser as CEO
NanoVibronix Names Doron Besser as CEO
Jun 4, 2025
01:46 PM EDT, 06/04/2025 (MT Newswires) -- NanoVibronix ( NAOV ) said Wednesday that Brian Murphy is retiring as chief executive officer and the board has appointed Doron Besser as CEO, effective immediately. Besser was CEO of ENvue Medical, which NanoVibronix ( NAOV ) acquired in February, according to a statement. Murphy will remain on the board as a director,...
Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses
Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses
Jun 4, 2025
01:50 PM EDT, 06/04/2025 (MT Newswires) -- Moleculin Biotech ( MBRX ) shares dropped about 19% in recent Wednesday trading after the company said no patients achieved complete response in the phase 1b/2 study of Annamycin for the treatment of soft tissue sarcoma lung metastases, a type of cancer. The trial, however, demonstrated a clinical benefit rate of 59.4%, primarily...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates
Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates
Jun 4, 2025
01:47 PM EDT, 06/04/2025 (MT Newswires) -- Biohaven ( BHVN ) shares were up over 4% in recent trading on Wednesday after the company said its two drug candidates are near market and it is doing phase three testing for four other indications. BHV-4157 for the treatment of spinocerebellar ataxia and BHV-2000 for spinal muscular atrophy are closer to the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved